{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:26:01Z","timestamp":1792801561608,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2023YFC2411800"],"award-info":[{"award-number":["2023YFC2411800"]}]},{"DOI":"10.13039\/501100004829","name":"Science and Technology Department of Sichuan Province","doi-asserted-by":"publisher","award":["2024YFHZ0329"],"award-info":[{"award-number":["2024YFHZ0329"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020207","name":"Sichuan Provincial Health Commission","doi-asserted-by":"crossref","award":["2025-106"],"award-info":[{"award-number":["2025-106"]}],"id":[{"id":"10.13039\/501100020207","id-type":"DOI","asserted-by":"crossref"}]},{"name":"\"From 0 To 1\" Innovation Research Project of Sichuan University","award":["2023SCUH0065"],"award-info":[{"award-number":["2023SCUH0065"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05813-w","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T15:46:29Z","timestamp":1766591189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Caihong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"5813_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/cc9358","volume":"15","author":"HM van Oudemans- Straaten","year":"2011","unstructured":"van Oudemans- Straaten HM, Kellum JA, Bellomo R. Clinical review: anticoagulation for continuous renal replacement therapy\u2013heparin or citrate? Crit Care. 2011;15:202. https:\/\/doi.org\/10.1186\/cc9358.","journal-title":"Crit Care"},{"key":"5813_CR2","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179\u2013184. https:\/\/doi.org\/10.1159\/000339789.","journal-title":"Nephron Clin Pract"},{"key":"5813_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/ACO.0b013e3283620224","volume":"26","author":"C Lanckohr","year":"2013","unstructured":"Lanckohr C, Hahnenkamp K, Boschin M. Continuous renal replacement therapy with regional citrate anticoagulation: do we really know the details? Curr Opin Anesthesiol. 2013;26:428. https:\/\/doi.org\/10.1097\/ACO.0b013e3283620224.","journal-title":"Curr Opin Anesthesiol"},{"key":"5813_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-023-00457-9","volume":"10","author":"S-Y Liu","year":"2023","unstructured":"Liu S-Y, Xu S-Y, Yin L, Yang T, Jin K, Zhang Q-B, et al. Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus. Mil Med Res. 2023;10:23. https:\/\/doi.org\/10.1186\/s40779-023-00457-9.","journal-title":"Mil Med Res"},{"key":"5813_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2012.08.016","volume":"27","author":"H-R Chua","year":"2012","unstructured":"Chua H-R, Baldwin I, Bailey M, Subramaniam A, Bellomo R. Circuit lifespan during continuous renal replacement therapy for combined liver and kidney failure. J Crit Care. 2012;27:e7447\u201315. https:\/\/doi.org\/10.1016\/j.jcrc.2012.08.016.","journal-title":"J Crit Care"},{"key":"5813_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s001340000691","volume":"26","author":"HK Tan","year":"2000","unstructured":"Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med. 2000;26:1652\u20137. https:\/\/doi.org\/10.1007\/s001340000691.","journal-title":"Intensive Care Med"},{"key":"5813_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035174","volume":"102","author":"Y Xie","year":"2023","unstructured":"Xie Y, Cheng Z, Deng C, Deng M, Zhang H. Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a systematic review and meta-analysis based on prospective, randomized, and controlled trials. Medicine (Baltimore). 2023;102:e35174. https:\/\/doi.org\/10.1097\/MD.0000000000035174.","journal-title":"Medicine (Baltimore)"},{"key":"5813_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-018-02567-w","volume":"109","author":"D Minakata","year":"2019","unstructured":"Minakata D, Fujiwara S-I, Ikeda T, Kawaguchi S-I, Toda Y, Ito S, et al. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies. Int J Hematol. 2019;109:141\u20136. https:\/\/doi.org\/10.1007\/s12185-018-02567-w.","journal-title":"Int J Hematol"},{"key":"5813_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/01.mat.0000209224.94089.bc","volume":"52","author":"M Miyata","year":"2006","unstructured":"Miyata M, Shirakawa T, Acharya B, Terao S, Gotoh A. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006;52:272\u20135. https:\/\/doi.org\/10.1097\/01.mat.0000209224.94089.bc.","journal-title":"ASAIO J"},{"key":"5813_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-022-00445-0","volume":"8","author":"M Abe","year":"2022","unstructured":"Abe M, Shiga H, Tatsumi H, Endo Y, Kikuchi Y, Suzuki Y, et al. Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes. Ren Replace Ther. 2022;8:58. https:\/\/doi.org\/10.1186\/s41100-022-00445-0.","journal-title":"Ren Replace Ther"},{"key":"5813_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","volume":"366","author":"Y Lang","year":"2022","unstructured":"Lang Y, Zheng Y, Qi B, Zheng W, Wei J, Zhao C, et al. Anticoagulation with nafamostat mesilate during extracorporeal life support. Int J Cardiol. 2022;366:71\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.022.","journal-title":"Int J Cardiol"},{"key":"5813_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000216866","volume":"23","author":"T Matsuo","year":"1993","unstructured":"Matsuo T, Kario K, Nakao K, Yamada T, Matsuo M. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis. 1993;23:135\u201341. https:\/\/doi.org\/10.1159\/000216866.","journal-title":"Haemostasis"},{"key":"5813_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3109\/0886022X.2011.647293","volume":"34","author":"NN Baek","year":"2012","unstructured":"Baek NN, Jang HR, Huh W, Kim Y-G, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. Ren Fail. 2012;34:279\u201385. https:\/\/doi.org\/10.3109\/0886022X.2011.647293.","journal-title":"Ren Fail"},{"key":"5813_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002392","volume":"94","author":"J-Y Choi","year":"2015","unstructured":"Choi J-Y, Kang Y-J, Jang HM, Jung H-Y, Cho J-H, Park S-H, et al. Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial. Medicine (Baltimore). 2015;94:e2392. https:\/\/doi.org\/10.1097\/MD.0000000000002392.","journal-title":"Medicine (Baltimore)"},{"key":"5813_CR15","first-page":"920","volume":"23","author":"S Han","year":"2004","unstructured":"Han S, \uae40\ud604\ucca0 \uae40\ud615\uaddc, \uc131\uc218\uc544 \uc870\uc6d0\uc6a9. A Multi-Center phase III clinical trial to assess the influence to bleeding and anticoagulant effect of Nafamostat mesilate (Futhan) in Hemodialysis patients with high bleeding-Risk. Kidney Res Clin Pract. 2004;23:920\u20136.","journal-title":"Kidney Res Clin Pract"},{"key":"5813_CR16","doi-asserted-by":"publisher","DOI":"10.5301\/ijao.5000191","author":"SD Hwang","year":"2013","unstructured":"Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat Mesilate for Anticoagulation in Continuous Renal Replacement Therapy. SAGE PublicationsSage UK: London, England;; 2013. [cited 2024 Sep 21].https:\/\/doi.org\/10.5301\/ijao.5000191.The International Journal of Artificial Organs [Internet]."},{"key":"5813_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03060-1","volume":"24","author":"S Kameda","year":"2023","unstructured":"Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study. BMC Nephrol. 2023;24:12. https:\/\/doi.org\/10.1186\/s12882-023-03060-1.","journal-title":"BMC Nephrol"},{"key":"5813_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108737","volume":"9","author":"YK Lee","year":"2014","unstructured":"Lee YK, Lee HW, Choi KH, Kim BS. Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study. PLoS One. 2014;9:e108737. https:\/\/doi.org\/10.1371\/journal.pone.0108737.","journal-title":"PLoS One"},{"key":"5813_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.athoracsur.2016.01.044","volume":"102","author":"JY Lim","year":"2016","unstructured":"Lim JY, Kim JB, Choo SJ, Chung CH, Lee JW, Jung SH. Anticoagulation during extracorporeal membrane oxygenation; nafamostat mesilate versus heparin. Ann Thorac Surg Neth. 2016;102:534\u20139. https:\/\/doi.org\/10.1016\/j.athoracsur.2016.01.044.","journal-title":"Ann Thorac Surg Neth"},{"key":"5813_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5301\/ijao.5000465","volume":"39","author":"S Makino","year":"2016","unstructured":"Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J Artif Organs United States. 2016;39:16\u201321. https:\/\/doi.org\/10.5301\/ijao.5000465.","journal-title":"Int J Artif Organs United States"},{"key":"5813_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082629","author":"H Kamijo","year":"2020","unstructured":"Kamijo H, Mochizuki K, Nakamura Y, Mori K, Ichikawa M, Nitta K, et al. Nafamostat mesylate improved survival outcomes of sepsis patients who underwent blood purification: a nationwide registry study in Japan. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9082629.","journal-title":"J Clin Med"},{"key":"5813_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2464830","volume":"47","author":"J Li","year":"2025","unstructured":"Li J, Wang L, Lu Y, Zhou Y, Chen Y. Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study. Ren Fail. 2025;47:2464830. https:\/\/doi.org\/10.1080\/0886022X.2025.2464830.","journal-title":"Ren Fail"},{"key":"5813_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01660-7","volume":"29","author":"D Liu","year":"2024","unstructured":"Liu D, Zhao J, Xia H, Dong S, Yan S, Zhuang Y, et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. Eur J Med Res. 2024;29:72. https:\/\/doi.org\/10.1186\/s40001-024-01660-7.","journal-title":"Eur J Med Res"},{"key":"5813_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.12998\/wjcc.v12.i1.68","volume":"12","author":"K Liu","year":"2024","unstructured":"Liu K, Li Z-H. Efficacy and safety of nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases United States. 2024;12:68\u201375. https:\/\/doi.org\/10.12998\/wjcc.v12.i1.68.","journal-title":"World J Clin Cases United States"},{"key":"5813_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.23876\/j.krcp.23.310","volume":"43","author":"T Kim","year":"2024","unstructured":"Kim T, Kim DE, Jo EM, Lee Y, Kim DW, Kim HJ, et al. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety. Kidney Res Clin Pract. 2024;43:469\u201379. https:\/\/doi.org\/10.23876\/j.krcp.23.310.","journal-title":"Kidney Res Clin Pract"},{"key":"5813_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.52547\/5j9v7385","volume":"19","author":"X Zhan","year":"2025","unstructured":"Zhan X, Qu X, Wu D, Wang G, Bai S, Ji T. Effects of nafamostat mesilate and systemic unfractionated heparin anticoagulation on coagulation, renal function, and 28-day survival status in critically ill AKI CRRT patients. Iran J Kidney Dis. 2025;19:41\u20139. https:\/\/doi.org\/10.52547\/5j9v7385.","journal-title":"Iran J Kidney Dis"},{"key":"5813_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/jbcr\/irad196","volume":"45","author":"Q Yue","year":"2024","unstructured":"Yue Q, Wu H, Xi M, Li F, Li T, Li Y. Filter lifespan, treatment effect, and influencing factors of continuous renal replacement therapy for severe burn patients. J Burn Care Res. 2024;45:764\u201370. https:\/\/doi.org\/10.1093\/jbcr\/irad196.","journal-title":"J Burn Care Res"},{"key":"5813_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000420222","volume":"93","author":"Y Ohtake","year":"1991","unstructured":"Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol. 1991;93:215\u20137. https:\/\/doi.org\/10.1159\/000420222.","journal-title":"Contrib Nephrol"},{"key":"5813_CR29","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","volume":"33","author":"S Uchino","year":"2007","unstructured":"Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33:1563\u201370. https:\/\/doi.org\/10.1007\/s00134-007-0754-4.","journal-title":"Intensive Care Med"},{"key":"5813_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13054-023-04519-1","volume":"27","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Liu C, Yang Y, Wang F, Zhang L, Fu P. Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care. 2023;27:222. https:\/\/doi.org\/10.1186\/s13054-023-04519-1.","journal-title":"Crit Care"},{"key":"5813_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/cc5937","volume":"11","author":"M Joannidis","year":"2007","unstructured":"Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care. 2007;11:218. https:\/\/doi.org\/10.1186\/cc5937.","journal-title":"Crit Care"},{"key":"5813_CR32","doi-asserted-by":"publisher","first-page":"S257","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:S257-98. https:\/\/doi.org\/10.1378\/chest.08-0674.","journal-title":"Chest"},{"key":"5813_CR33","doi-asserted-by":"publisher","DOI":"10.4236\/ojem.2022.104014","author":"K Konishi","year":"2022","unstructured":"Konishi K, Inoue S, Kawaguchi M. Evaluation of the pharmacokinetics of Nafamostat mesylate during continuous renal replacement therapy. Open J Emerg Med. 2022. 10:157-167. https:\/\/doi.org\/10.4236\/ojem.2022.104014","journal-title":"Open J Emerg Med"},{"key":"5813_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1177\/1076029607309184","volume":"14","author":"T Matsuo","year":"2008","unstructured":"Matsuo T, Wanaka K. Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. Clin Appl Thromb Hemost. 2008;14:459\u201364. https:\/\/doi.org\/10.1177\/1076029607309184.","journal-title":"Clin Appl Thromb Hemost"},{"key":"5813_CR35","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1248\/bpb.31.1985","volume":"31","author":"Y-G Cao","year":"2008","unstructured":"Cao Y-G, Chen Y-C, Hao K, Zhang M, Liu X-Q. An in vivo approach for globally estimating the drug flow between blood and tissue for Nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31:1985\u20139. https:\/\/doi.org\/10.1248\/bpb.31.1985.","journal-title":"Biol Pharm Bull"},{"key":"5813_CR36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2133\/dmpk.21.147","volume":"21","author":"S Yamaori","year":"2006","unstructured":"Yamaori S, Fujiyama N, Kushihara M, Funahashi T, Kimura T, Yamamoto I, et al. Involvement of human blood arylesterases and liver microsomal carboxylesterases in Nafamostat hydrolysis. Drug Metab Pharmacokinet. 2006;21:147\u201355. https:\/\/doi.org\/10.2133\/dmpk.21.147.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"5813_CR37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.19842\/j.cnki.issn.0253-9934.2024.03.001","volume":"47","author":"Society of Nephrology, Shanghai Medical Association, Expert Consensus on Application of Nafamostat Mesilate in Anticoagulation for Blood Purification Writing Group","year":"2024","unstructured":"Society of Nephrology, Shanghai Medical Association, Expert Consensus on Application of Nafamostat Mesilate in Anticoagulation for Blood Purification Writing Group. Expert consensus on application of nafamostat mesilate in anticoagulation for blood purification (in Chinese). SMJ. 2024;47(3):129\u201344. https:\/\/doi.org\/10.19842\/j.cnki.issn.0253-9934.2024.03.001.","journal-title":"SMJ"},{"key":"5813_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1541131","author":"DH Lee","year":"2025","unstructured":"Lee DH, Lee JH, Jang JH, Kim YK, Kang G, Jung SY, et al. Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1541131.","journal-title":"Front Pharmacol"},{"key":"5813_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/bs.pmbts.2019.02.003","volume":"163","author":"C Hao","year":"2019","unstructured":"Hao C, Sun M, Wang H, Zhang L, Wang W. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21\u201339. https:\/\/doi.org\/10.1016\/bs.pmbts.2019.02.003.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"5813_CR40","doi-asserted-by":"publisher","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64s","volume":"119","author":"J Hirsh","year":"2001","unstructured":"Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001;119:64S-94S. https:\/\/doi.org\/10.1378\/chest.119.1_suppl.64s.","journal-title":"Chest"},{"key":"5813_CR41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1080\/0886022X.2022.2105233","volume":"44","author":"Y Lin","year":"2022","unstructured":"Lin Y, Shao Y, Liu Y, Yang R, Liao S, Yang S, et al. Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis. Ren Fail. 2022;44:1263\u201379. https:\/\/doi.org\/10.1080\/0886022X.2022.2105233.","journal-title":"Ren Fail"},{"key":"5813_CR42","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1182\/blood-2005-04-1546","volume":"106","author":"N Martel","year":"2005","unstructured":"Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106:2710\u20135. https:\/\/doi.org\/10.1182\/blood-2005-04-1546.","journal-title":"Blood"},{"key":"5813_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/039139881003300302","volume":"33","author":"G-R Kleger","year":"2010","unstructured":"Kleger G-R, F\u00e4ssler E. Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs. 2010;33:139\u201346. https:\/\/doi.org\/10.1177\/039139881003300302.","journal-title":"Int J Artif Organs"},{"key":"5813_CR44","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000380904","volume":"39","author":"L Schilder","year":"2015","unstructured":"Schilder L, Nurmohamed SA, ter Wee PM, Paauw NJ, Girbes ARJ, Beishuizen A, et al. Coagulation, fibrinolysis and inhibitors in failing filters during continuous venovenous hemofiltration in critically ill patients with acute kidney injury: effect of anticoagulation modalities. Blood Purif. 2015;39:297\u2013305. https:\/\/doi.org\/10.1159\/000380904.","journal-title":"Blood Purif"},{"key":"5813_CR45","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/cc11403","volume":"16","author":"S Morabito","year":"2012","unstructured":"Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, Strampelli E, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care. 2012;16:R111. https:\/\/doi.org\/10.1186\/cc11403.","journal-title":"Crit Care"},{"key":"5813_CR46","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s001340050892","volume":"25","author":"ZJ Hu","year":"1999","unstructured":"Hu ZJ, Iwama H, Suzuki R, Kobayashi S, Akutsu I. Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate. Intensive Care Med. 1999;25:524\u20137. https:\/\/doi.org\/10.1007\/s001340050892.","journal-title":"Intensive Care Med"},{"key":"5813_CR47","doi-asserted-by":"publisher","unstructured":"H N, K T. Correlation between serum Nafamostat mesilate and activated coagulation time during continuous hemodiafiltration. Artificial organs [Internet]. Artif Organs; 2005 [cited 2025 Nov 13];29. https:\/\/doi.org\/10.1111\/j.1525-1594.2005.29061.x","DOI":"10.1111\/j.1525-1594.2005.29061.x"},{"key":"5813_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/1744-9987.13545","volume":"24","author":"N Kuriyama","year":"2020","unstructured":"Kuriyama N, Matsumoto K, Morita K, Shimomura Y, Hara Y, Hasegawa D, et al. Nafamostat mesilate inhibits linezolid metabolism via its antioxidant effects. Ther Apher Dial. 2020;24:499\u2013502. https:\/\/doi.org\/10.1111\/1744-9987.13545.","journal-title":"Ther Apher Dial"},{"key":"5813_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000045822","volume":"86","author":"N Higuchi","year":"2000","unstructured":"Higuchi N, Yamazaki H, Kikuchi H, Gejyo F. Anaphylactoid reaction induced by a protease inhibitor, Nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron. 2000;86:400\u20131. https:\/\/doi.org\/10.1159\/000045822.","journal-title":"Nephron"},{"key":"5813_CR50","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/0306-3623(95)00072-0","volume":"26","author":"S Muto","year":"1995","unstructured":"Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by Nafamostat mesilate. Gen Pharmacol. 1995;26:1627\u201332. https:\/\/doi.org\/10.1016\/0306-3623(95)00072-0.","journal-title":"Gen Pharmacol"},{"key":"5813_CR51","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/ndt\/7.9.980a","volume":"7","author":"H Okada","year":"1992","unstructured":"Okada H, Suzuki H, Deguchi N, Saruta T. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, Nafamostate mesilate. Nephrol Dial Transplant. 1992;7:980. https:\/\/doi.org\/10.1093\/ndt\/7.9.980a.","journal-title":"Nephrol Dial Transplant"},{"key":"5813_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.6140","volume":"10","author":"N Shioya","year":"2022","unstructured":"Shioya N, Inoue N, Sato H, Iwahara M, Sato T, Tsukamoto Y, et al. Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis. Clin Case Rep. 2022;10:e6140. https:\/\/doi.org\/10.1002\/ccr3.6140.","journal-title":"Clin Case Rep"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05813-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:36:15Z","timestamp":1770888975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-025-05813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5813"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05813-w","relation":{"references":[{"id-type":"doi","id":"10.5301\/ijao.5000191","asserted-by":"subject"}]},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}